Annals of Surgical Oncology

, Volume 22, Issue 5, pp 1658–1663 | Cite as

Morbidity of the Abdominal Wall Resection and Reconstruction After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC)

  • Maria F. Nunez
  • Armando Sardi
  • Carol Nieroda
  • William Jimenez
  • Michelle Sittig
  • Ryan MacDonald
  • Nail Aydin
  • Vladimir Milovanov
  • Vadim Gushchin
Gastrointestinal Oncology



CRS/HIPEC has evolved as a therapeutic option for selected patients with peritoneal surface malignancies. To achieve complete cytoreduction (CC), some patients require extensive abdominal-wall resection (AWR) and subsequent complex reconstructions, which may be associated with wound complications (WC) and delay of postoperative cancer therapy.


Review of a prospective database of 350 patients revealed 213 patients with peritoneal carcinomatosis who underwent AWR due to suspected or proven wound/port site metastases during CRS/HIPEC. Tumor origin included: appendix, colon, ovarian, peritoneal mesothelioma, primary peritoneal, and others. WC were related to peritoneal carcinomatosis index (PCI), CC score, length of surgery, type of AWR and closure, blood transfusion, and albumin levels using binary logistic regression (odds ratios (OR) and 95 % CIs) analysis.


PCI ≥ 20 was found in 151 (71 %), CC was achieved in 178 (84 %). Mean length of surgery was 613 min. Postoperative WC were detected in 49 of 213 (23 %) patients, 13 (6 %) had Grade III (according to Clavien–Dindo’s classification) WC, and led to delay of postoperative chemotherapy. WC occurred in 21 of 64 (32.8 %) patients with excision of port sites (odds ratio [OR] = 2.11, confidence interval [CI] = 1.09–4.10, p = 0.026). Primary fascial closure was performed in 191 of 213 (89.7 %) patients, 40 (21 %) of whom had WC. Mesh-assisted abdominal wall reconstruction was required in 22 of 213 (10.3 %) patients, of whom 9 (40.9 %) had WC (OR = 2.61, CI = 1.04–6.55, p = 0.035).


Port-site excision and mesh-assisted abdominal wall reconstruction were associated with higher incidence of postoperative WC following CRS/HIPEC. The implications of these preliminary findings may need to be considered during surgical planning for these patients.


Peritoneal Carcinomatosis Wound Complication Port Site Peritoneal Cancer Index Complete Cytoreduction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The authors declare that there is no financial or commercial interest in the present study.


  1. 1.
    Elias D, Lefevre JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009;27(5):681–5.CrossRefPubMedGoogle Scholar
  2. 2.
    Elias D, Goere D, Dumont F, et al. Role of hyperthermic intraoperative peritoneal chemotherapy in the management of peritoneal metastases. Eur J Cancer. 2014;50(2):332–40.CrossRefPubMedGoogle Scholar
  3. 3.
    Omohwo C, Nieroda CA, Studeman KD, et al. Complete cytoreduction offers long-term survival in patients with peritoneal carcinomatosis from appendiceal tumors of unfavorable histology. J Am Coll Surg. 2009;209(3):308–12.CrossRefPubMedGoogle Scholar
  4. 4.
    Sommariva A, Pilati P, Rossi CR. Cyto-reductive surgery combined with hyperthermic intra-peritoneal chemotherapy for peritoneal surface malignancies: current treatment and results. Cancer Treat Rev. 2012;38(4):258–68.CrossRefPubMedGoogle Scholar
  5. 5.
    El HH, Gushchin V, Francis J, et al. The role of cytoreductive surgery and heated intraperitoneal chemotherapy (CRS/HIPEC) in patients with high-grade appendiceal carcinoma and extensive peritoneal carcinomatosis. Ann Surg Oncol. 2012;19(1):110–4.CrossRefGoogle Scholar
  6. 6.
    Erinjeri JP, Fong AJ, Kemeny NE, Brown KT, Getrajdman GI, Solomon SB. Timing of administration of bevacizumab chemotherapy affects wound healing after chest wall port placement. Cancer. 2011;117(6):1296–301.CrossRefPubMedGoogle Scholar
  7. 7.
    Gordon CR, Rojavin Y, Patel M, et al. A review on bevacizumab and surgical wound healing: an important warning to all surgeons. Ann Plast Surg. 2009;62(6):707–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Adachi S, Kokura S, Okayama T, et al. Effect of hyperthermia combined with gemcitabine on apoptotic cell death in cultured human pancreatic cancer cell lines. Int J Hyperthermia. 2009;25(3):210–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Sugarbaker PH. Laboratory and clinical basis for hyperthermia as a component of intracavitary chemotherapy. Int J Hyperthermia. 2007;23(5):431–42.CrossRefPubMedGoogle Scholar
  10. 10.
    Aarts F, Bleichrodt RP, de Man B, Lomme R, Boerman OC, Hendriks T. The effects of adjuvant experimental radioimmunotherapy and hyperthermic intraperitoneal chemotherapy on intestinal and abdominal healing after cytoreductive surgery for peritoneal carcinomatosis in the rat. Ann Surg Oncol. 2008;15(11):3299–307.Google Scholar
  11. 11.
    Chua TC, Yan TD, Saxena A, Morris DL. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure? a systematic review of morbidity and mortality. Ann Surg. 2009;249(6):900–7.CrossRefPubMedGoogle Scholar
  12. 12.
    Sugarbaker PH, Alderman R, Edwards G, et al. Prospective morbidity and mortality assessment of cytoreductive surgery plus perioperative intraperitoneal chemotherapy to treat peritoneal dissemination of appendiceal mucinous malignancy. Ann Surg Oncol. 2006;13(5):635–44.CrossRefPubMedGoogle Scholar
  13. 13.
    Franko J, Gusani NJ, Holtzman MP, et al. Multivisceral resection does not affect morbidity and survival after cytoreductive surgery and chemoperfusion for carcinomatosis from colorectal cancer. Ann Surg Oncol. 2008;15(11):3065–72.CrossRefPubMedGoogle Scholar
  14. 14.
    Haslinger M, Francescutti V, Attwood K, et al. A contemporary analysis of morbidity and outcomes in cytoreduction/hyperthermic intraperitoneal chemoperfusion. Cancer Med. 2013;2(3):334–42.CrossRefPubMedCentralPubMedGoogle Scholar
  15. 15.
    Reuter NP, Macgregor JM, Woodall CE, et al. Preoperative performance status predicts outcome following heated intraperitoneal chemotherapy. Am J Surg. 2008;196(6):909–13.CrossRefPubMedGoogle Scholar
  16. 16.
    Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359–74.CrossRefPubMedGoogle Scholar
  17. 17.
    Esquivel J, Elias D, Baratti D, Kusamura S, Deraco M. Consensus statement on the loco regional treatment of colorectal cancer with peritoneal dissemination. J Surg Oncol. 2008;98(4):263–7.CrossRefPubMedGoogle Scholar
  18. 18.
    Sugarbaker PH. Peritonectomy procedures. Surg Oncol Clin N Am. 2003;12(3):703–27, xiii.CrossRefPubMedGoogle Scholar
  19. 19.
    Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13.CrossRefPubMedCentralPubMedGoogle Scholar
  20. 20.
    Fuks D, Regimbeau JM, Pessaux P, et al. Is port-site resection necessary in the surgical management of gallbladder cancer? J Visc Surg. 2013;150(4):277–84.CrossRefPubMedGoogle Scholar
  21. 21.
    Maker AV, Butte JM, Oxenberg J, et al. Is port site resection necessary in the surgical management of gallbladder cancer? Ann Surg Oncol. 2012;19(2):409–17.CrossRefPubMedGoogle Scholar
  22. 22.
    Nguyen MT, Berger RL, Hicks SC, et al. Comparison of outcomes of synthetic mesh versus suture repair of elective primary ventral herniorrhaphy: a systematic review and meta-analysis. JAMA Surg. 2014;149(5):415–21.Google Scholar
  23. 23.
    White TJ, Santos MC, Thompson JS. Factors affecting wound complications in repair of ventral hernias. Am Surg. 1998;64(3):276–80.PubMedGoogle Scholar
  24. 24.
    Boutros C, Somasundar P, Espat NJ. Early results on the use of biomaterials as adjuvant to abdominal wall closure following cytoreduction and hyperthermic intraperitoneal chemotherapy. World J Surg Oncol. 2010;8:72.CrossRefPubMedCentralPubMedGoogle Scholar
  25. 25.
    Fagotti A, Fanfani F, Ludovisi M, et al. Role of laparoscopy to assess the chance of optimal cytoreductive surgery in advanced ovarian cancer: a pilot study. Gynecol Oncol. 2005;96(3):729–35.CrossRefPubMedGoogle Scholar
  26. 26.
    Garofalo A, Valle M. Laparoscopy in the management of peritoneal carcinomatosis. Cancer J. 2009;15(3):190–5.CrossRefPubMedGoogle Scholar
  27. 27.
    Laterza B, Kusamura S, Baratti D, Oliva GD, Deraco M. Role of explorative laparoscopy to evaluate optimal candidates for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal mesothelioma. In Vivo 2009;23(1):187–90.Google Scholar
  28. 28.
    Valle M, Garofalo A. Laparoscopic staging of peritoneal surface malignancies. Eur J Surg Oncol. 2006;32(6):625–7.CrossRefPubMedGoogle Scholar
  29. 29.
    Valle M, Federici O, Garofalo A. Patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, and role of laparoscopy in diagnosis, staging, and treatment. Surg Oncol Clin N Am. 2012;21(4):515–31.CrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2014

Authors and Affiliations

  • Maria F. Nunez
    • 1
  • Armando Sardi
    • 1
  • Carol Nieroda
    • 1
  • William Jimenez
    • 1
  • Michelle Sittig
    • 1
  • Ryan MacDonald
    • 1
  • Nail Aydin
    • 1
  • Vladimir Milovanov
    • 1
  • Vadim Gushchin
    • 1
  1. 1.Institute for Cancer Care at Mercy Medical CenterBaltimoreUSA

Personalised recommendations